According to Bloomberg, NewLimit, an longevity startup founded by Coinbase co-founder Brian Armstrong, announced the completion of a $130 million Series B funding round, with a company valuation reaching $810 million. The round was led by Kleiner Perkins, with other investors including Khosla Ventures and Human Capital.

NewLimit aims to delay aging and restore cell function by reprogramming specific proteins within human cells. The company has raised a total of $275 million so far, including $105 million initially funded by the founders in 2021 and $40 million in 2023.

According to Bloomberg, NewLimit, a longevity startup founded by Coinbase co-founder Brian Armstrong, announced the completion of a $130 million Series B funding round, with a company valuation reaching $810 million. The round was led by Kleiner Perkins, with other investors including Khosla Ventures and Human Capital. NewLimit aims to delay aging and restore cellular functions by reprogramming specific proteins in human cells. The company has raised a total of $275 million so far, including $105 million funded by the founder at its inception in 2021 and $40 million in 2023.

NewLimit Announces Completion of $130 Million Series B Financing, Company Valued at $810 Million